1
|
Cserepes M, Nelhűbel GA, Meilinger-Dobra M, Herczeg A, Türk D, Hegedűs Z, Svajda L, Rásó E, Ladányi A, Csikó KG, Kenessey I, Szöőr Á, Vereb G, Remenár É, Tóvári J. EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. Cancers (Basel) 2022; 14:cancers14102407. [PMID: 35626010 PMCID: PMC9140151 DOI: 10.3390/cancers14102407] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Revised: 05/02/2022] [Accepted: 05/11/2022] [Indexed: 02/05/2023] Open
Abstract
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the epidermal growth factor receptor (EGFR). Cetuximab augments the effect of chemotherapy; however, a significant number of patients show therapy resistance. The mechanism of resistance is yet to be unveiled, although extracellular alterations of the receptor have been reported, and their role in cetuximab failure has been proposed. Aims: Here, we investigate possible effects of the multi-exon deletion variant (EGFRvIII), and the single nucleotide polymorphism EGFR R521K on cetuximab efficacy. Results: Our results show that in HNSCC patients, the EGFRvIII allele frequency is under 1%; therefore, it cannot lead to common resistance. EGFR R521K, present in 42% of the patients, is investigated in vitro in four HNSCC cell lines (two wild-type and two heterozygous for EGFR R521K). While no direct effect is found to be related to the EGFR status, cells harboring R521K show a reduced sensitivity in ADCC experiments and in vivo xenograft experiments. However, this preclinical difference is not reflected in the progression-free or overall survival of HNSCC patients. Furthermore, NK cell and macrophage presence in tumors is not related to EGFR R521K. Discussion: Our results suggest that EGFR R521K, unlike reported previously, is unable to cause cetuximab resistance in HNSCC patients; therefore, its screening before therapy selection is not justifiable.
Collapse
Affiliation(s)
- Mihály Cserepes
- Department of Experimental Pharmacology, National Institute of Oncology, Ráth György utca 7-9, H-1122 Budapest, Hungary; (M.C.); (G.A.N.); (D.T.); (Z.H.); (L.S.)
- National Tumor Biology Laboratory, National Institute of Oncology, H-1122 Budapest, Hungary; (A.L.); (I.K.)
| | - Györgyi A. Nelhűbel
- Department of Experimental Pharmacology, National Institute of Oncology, Ráth György utca 7-9, H-1122 Budapest, Hungary; (M.C.); (G.A.N.); (D.T.); (Z.H.); (L.S.)
| | - Mónika Meilinger-Dobra
- The Multidisciplinary Head and Neck Cancer Center, National Institute of Oncology, H-1122 Budapest, Hungary; (M.M.-D.); (A.H.); (É.R.)
| | - Adrienn Herczeg
- The Multidisciplinary Head and Neck Cancer Center, National Institute of Oncology, H-1122 Budapest, Hungary; (M.M.-D.); (A.H.); (É.R.)
| | - Dóra Türk
- Department of Experimental Pharmacology, National Institute of Oncology, Ráth György utca 7-9, H-1122 Budapest, Hungary; (M.C.); (G.A.N.); (D.T.); (Z.H.); (L.S.)
| | - Zita Hegedűs
- Department of Experimental Pharmacology, National Institute of Oncology, Ráth György utca 7-9, H-1122 Budapest, Hungary; (M.C.); (G.A.N.); (D.T.); (Z.H.); (L.S.)
| | - Laura Svajda
- Department of Experimental Pharmacology, National Institute of Oncology, Ráth György utca 7-9, H-1122 Budapest, Hungary; (M.C.); (G.A.N.); (D.T.); (Z.H.); (L.S.)
| | - Erzsébet Rásó
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary;
| | - Andrea Ladányi
- National Tumor Biology Laboratory, National Institute of Oncology, H-1122 Budapest, Hungary; (A.L.); (I.K.)
- Department of Surgical and Molecular Pathology, National Institute of Oncology, H-1122 Budapest, Hungary
| | - Kristóf György Csikó
- Department of Chest and Abdominal Tumors and Clinical Pharmacology, National Institute of Oncology, H-1122 Budapest, Hungary;
| | - István Kenessey
- National Tumor Biology Laboratory, National Institute of Oncology, H-1122 Budapest, Hungary; (A.L.); (I.K.)
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary;
- Hungarian Cancer Registry, National Institute of Oncology, H-1122 Budapest, Hungary
| | - Árpád Szöőr
- Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; (Á.S.); (G.V.)
| | - György Vereb
- Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; (Á.S.); (G.V.)
| | - Éva Remenár
- The Multidisciplinary Head and Neck Cancer Center, National Institute of Oncology, H-1122 Budapest, Hungary; (M.M.-D.); (A.H.); (É.R.)
| | - József Tóvári
- Department of Experimental Pharmacology, National Institute of Oncology, Ráth György utca 7-9, H-1122 Budapest, Hungary; (M.C.); (G.A.N.); (D.T.); (Z.H.); (L.S.)
- National Tumor Biology Laboratory, National Institute of Oncology, H-1122 Budapest, Hungary; (A.L.); (I.K.)
- Correspondence: ; Tel.: +36-1-224-8778; Fax: +36-1-224-8724
| |
Collapse
|
2
|
Remenár É, Dóczi R, Dirner A, Sipos A, Perjési A, Tihanyi D, Vodicska B, Lakatos D, Horváth K, Kajáry K, Schwáb R, Déri J, Lengyel CG, Várkondi E, Vályi-Nagy I, Peták I. Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy. JCO Precis Oncol 2022; 6:e2100344. [PMID: 35005996 DOI: 10.1200/po.21.00344] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Éva Remenár
- Buda Hospitaller Order of St John of God, Budapest, Hungary
| | - Róbert Dóczi
- Oncompass Medicine Hungary Ltd, Budapest, Hungary
| | - Anna Dirner
- Oncompass Medicine Hungary Ltd, Budapest, Hungary
| | - Anna Sipos
- Oncompass Medicine Hungary Ltd, Budapest, Hungary
| | | | - Dóra Tihanyi
- Oncompass Medicine Hungary Ltd, Budapest, Hungary
| | | | - Dóra Lakatos
- Oncompass Medicine Hungary Ltd, Budapest, Hungary
| | | | | | - Richárd Schwáb
- Oncompass Medicine Hungary Ltd, Budapest, Hungary.,MiND Klinika Kft, Budapest, Hungary
| | - Júlia Déri
- Oncompass Medicine Hungary Ltd, Budapest, Hungary
| | | | | | - István Vályi-Nagy
- Centrum Hospital of Southern Pest, National Hematology and Infectology Institute, Budapest, Hungary
| | - István Peták
- Oncompass Medicine Hungary Ltd, Budapest, Hungary.,Department of Pharmacology, Semmelweis University, Budapest, Hungary.,Department of Pharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL
| |
Collapse
|
3
|
Szturz P, Vinches M, Remenár É, van Herpen CML, Abdeddaim C, Stewart JS, Fortpied C, Vermorken JB. Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients. Eur J Cancer 2021; 156:109-118. [PMID: 34425403 DOI: 10.1016/j.ejca.2021.07.034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 07/19/2021] [Accepted: 07/26/2021] [Indexed: 11/16/2022]
Abstract
BACKGROUND In the TAX 323 (EORTC 24971) phase III trial enrolling patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN), the addition of docetaxel (T) to cisplatin and 5-fluorouracil (PF)-based induction chemotherapy prior to definite radiotherapy significantly improved progression-free survival (PFS) and overall survival (OS). METHODS The data were updated for PFS, OS and treatment-related long-term side-effects. Baseline clinical and laboratory data of 17 variables were collected and subjected to univariate and multivariate prognostic factor analyses for OS. RESULTS All 358 patients randomised between 1999 and 2002 were included in the long-term analysis with a median follow-up of 8.6 years. The primary end-point of PFS remained significantly improved with TPF compared with PF (adjusted hazard ratio [HR], 0.70; 95% CI, 0.56-0.88, p = 0.002), translating into a persisting benefit in OS (adjusted HR, 0.75; 95% CI, 0.60-0.95, p = 0.015). Long-term side-effects in the TPF/PF arms comprised tracheostomy (7%/5%), feeding tube dependency (3%/6%) and gastrostomy (11%/11%). Second malignancy occurred in 8%/3%, respectively. Out of 177 patients randomised to the TPF arm, 160 were included in the multivariate analysis. Grade 2 or more dysphagia (p = 0.002) and grade 2 or more pain (p = 0.004) at baseline were identified as independent negative prognostic factors. In addition, OS differed across primary tumour sites (p = 0.027) and was worse in patients with a higher N-stage (p = 0.025). CONCLUSIONS In LA-SCCHN patients treated with sequential chemoradiotherapy, TPF induction chemotherapy demonstrated long-lasting efficacy, superior to the PF regimen. Higher-grade dysphagia and pain are unfavourable prognosticators.
Collapse
Affiliation(s)
- Petr Szturz
- Medical Oncology, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Marie Vinches
- The European Organisation for Research and Treatment of Cancer, Brussels, Belgium
| | - Éva Remenár
- Hospitalier Order of Saint John of God Hospital Buda, Budapest, Hungary
| | - Carla M L van Herpen
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
| | | | | | - Catherine Fortpied
- The European Organisation for Research and Treatment of Cancer, Brussels, Belgium
| | - Jan B Vermorken
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
| |
Collapse
|
4
|
Révész M, Oberna F, Remenár É, Takácsi-Nagy Z. Clinical importance of retropharyngeal lymph node metastases. Orv Hetil 2021; 162:997-1003. [PMID: 34148023 DOI: 10.1556/650.2021.32063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Accepted: 11/08/2020] [Indexed: 11/19/2022]
Abstract
Összefoglaló. A retropharyngealis nyirokcsomóáttétek incidenciája a primer fej-nyaki daganat lokalizációjától függ. Leggyakrabban az előrehaladott vagy recidív nasopharynx-carcinomák esetén fordul elő, de III-IV. stádiumú oro- és hypopharynxtumorok esetén is megjelenhetnek. Non-nasopharyngealis primer tumoroknál a manifesztációjuk kedvezőtlen prognosztikai faktornak tekinthető, melynek hátterében a diagnosztikus nehézség miatti késői detektálás, a kifejezetten nehéz sebészi eltávolíthatóság, valamint az agresszív biológiai viselkedés állhat. Az esetismertetésünkben bemutatásra kerülő, 58 éves betegünknél bal oldali elülső szájfenéki primer tumort diagnosztizáltunk azonos oldali nyaki és retropharyngealis nyirokcsomó-metastasissal, mely a nemzetközi irodalom alapján extrém raritás, incidenciája kevesebb mint 1%. A retropharyngealis nyirokcsomók diagnosztikájában a lokalizáció miatt a képalkotóknak jut hangsúlyosabb szerep. Elhelyezkedésük nemcsak diagnosztikus, hanem sebésztechnikai kihívást is jelentenek az életfontosságú anatómiai képletek közelsége, illetve a szűk feltárási viszonyok miatt. Ilyenformán ezek a műtétek csak intenzív osztályos háttérrel és kellő jártassággal rendelkező centrumokban végezhetők. Az alapvetően rossz prognózist a korai diagnózis és a multimodális terápia kedvezően befolyásolja. Esetünkben a komplex kezeléssel (sebészi terápia és posztoperatív radiokemoterápia) sikerült lokoregionális tumormentességet elérni, és ezzel a teljes és a betegségmentes túlélési időt növelni. Orv Hetil. 2021; 162(25): 997-1003. Summary. The incidence of retropharyngeal lymph node metastasis depends on the localization of the primary head and neck cancer. Involved nodes are seen most commonly in cases of advanced or recurrent nasopharyngeal carcinoma, however, they might occur with stage III-IV oro- and hypopharyngeal tumours. The involvement of retropharyngeal lymph nodes has been associated with poor outcome of non-nasopharyngeal primary tumours, which might be explained by the delayed diagnosis, the difficult surgical procedure in the retropharyngeal space, and the aggressive nature of the disease. Here we present the case of a 58-year-old patient with an anterior oral cavity tumour on the left side with ipsilateral cervical lymph node and retropharyngeal lymph node metastases, which has been noted an extreme rarity in the literature with less than 1% incidence. Due to the localization of the retropharyngeal lymph nodes, the detection is based on imaging modalities. It represents a challenge for diagnosis and surgical treatment due to the close proximity of vital anatomical structures. Accordingly, these operations should only be performed in specialist surgical centres with intensive care units. The early diagnosis and the multimodality treatment might have a positive effect on the poor prognosis. In our case, we managed to achieve locoregional disease-free status with the complex treatment (surgical therapy and postoperative radiochemotherapy) and increase the overall and the disease-free survival. Orv Hetil. 2021; 162(25): 997-1003.
Collapse
Affiliation(s)
- Mónika Révész
- 1 Oszágos Onkológiai Intézet, Fej-Nyaki Daganatok Multidiszciplináris Központ, Budapest, Ráth György u. 7-9., 1122
| | - Ferenc Oberna
- 1 Oszágos Onkológiai Intézet, Fej-Nyaki Daganatok Multidiszciplináris Központ, Budapest, Ráth György u. 7-9., 1122
| | - Éva Remenár
- 1 Oszágos Onkológiai Intézet, Fej-Nyaki Daganatok Multidiszciplináris Központ, Budapest, Ráth György u. 7-9., 1122
| | - Zoltán Takácsi-Nagy
- 2 Országos Onkológiai Intézet, Sugárterápiás Központ, Budapest.,3 Semmelweis Egyetem, Általános Orvostudományi Kar, Onkológiai Tanszék, Budapest
| |
Collapse
|
5
|
Cserepes M, Nelhűbel GA, Meilinger-Dobra M, Surguta SE, Rásó E, Ladányi A, Kenessey I, Szöőr Á, Vereb G, Remenár É, Tóvári J. [Consequences of extracellular alterations of EGFR on cetuximab therapy in HNSCC]. Magy Onkol 2021; 65:188-195. [PMID: 34081766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Accepted: 05/12/2021] [Indexed: 06/12/2023]
Abstract
Head and neck squamous cell carcinomas (HNSCC) take many lifes worldwide. Patients with recurrent/metastatic disease receive combination chemotherapy containing anti-EGFR antibody cetuximab. However, resistance often hurdles therapy. The mechanism is yet to unveil, although EGFR extracellular alterations and activity of c-Met signaling were accused. We investigated the effects of EGFR-vIII and EGFR-R521K on cetuximab efficacy in HNSCC in cellular, xenograft, and clinical setup. Furthermore, we investigated the efficacy of c-Met inhibition in HNSCC in vitro and in vivo. We showed that EGFR-vIII is very rare in HNSCC, while the common R521K polymorphism abolishes antibody-dependent cellular cytotoxicity and in vivo antitumor effect of cetuximab. This selectivity was not reflected in immunophenotype or survival data of HNSCC patients, suggesting a more complex mechanism behind. Interestingly, c-Met inhibitor SU11274 was more effective in cetuximab-resistant, EGFR R521K heterozygous cells and xenografts, raising the possible importance of simultaneous targeting of the two receptors.
Collapse
Affiliation(s)
- Mihály Cserepes
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Györgyi A Nelhűbel
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Mónika Meilinger-Dobra
- Fej-nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary
| | - Sára Eszter Surguta
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Erzsébet Rásó
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary
| | - Andrea Ladányi
- Sebészeti és Molekuláris Patológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
| | - István Kenessey
- Nemzeti Rákregiszter, Országos Onkológiai Intézet, Budapest, Hungary
| | - Árpád Szöőr
- Általános Orvostudományi Kar, Debreceni Egyetem, Biofizikai és Sejtbiológiai Intézet, Debrecen, Hungary
| | - György Vereb
- Általános Orvostudományi Kar, Debreceni Egyetem, Biofizikai és Sejtbiológiai Intézet, Debrecen, Hungary
| | - Éva Remenár
- Fej-nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary
| | - József Tóvári
- Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
| |
Collapse
|
6
|
Cserepes MT, Hegedus Z, Ranđelović I, Kenessey I, Meilinger-Dobra M, Csikó KG, Ladanyi A, Remenár É, Tovari J. Abstract 1863: Correlations of genetic variation R521K of EGF receptor and the in vitro, in vivo and clinical phenotypes of head and neck cancers after cetuximab treatment. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-1863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Squamous cell carcinomas of the Head and Neck region (HNSCCs) have about 600.000 new cases every year. Advanced disease is treated by radio-chemotherapy, which has ambiguous success. Cetuximab, a monoclonal antibody against EGF receptor, is proven to be useful in combination therapy, thus it is in clinical use in HNSCC. However, a large number of patients show therapy resistance and do not benefit from combined therapy. EGF receptor is a widely used target in the therapy against cancer cells. Antibodies (as cetuximab) and inhibitors (TKI) are in use. However, genetic variations of the receptor are described to influence therapy efficacy. The extracellular missense polymorphism R521K of the receptor is reported to be abundant in HNSCC. However, its role in therapy outcome is yet to be cleared. In the present work, we mapped the possible effects of cetuximab therapy in wild type and mutant genotype HNSCCs. We selected two wild type (Pe/Ca-PJ41, Cal27) and two R521K (Pe/Ca-PJ15, FaDu) cell lines, performed in vitro proliferation tests and antibody binding assays, measured in vitro Antigen-Dependent Cellular Cytotoxicity (ADCC), and quantified receptor phosphorylation inhibition by cetuximb. In our in vivo xenograft experiments, we analyzed subcutaneous tumor growth by cetuximab, in combination with inhibition of NK cell and macrophage activity. Importantly, we analyzed clinical samples in the National Institute of Oncology, originated from 95 relapsed HNSCC patients treated with cetuximab to reveal any connections between EGFR R521K single nucleotide polymorphism and clinical outcome. In cell lines, cetuximab did not show significant cytotoxic effects, but was effective in the ADCC assay. Significantly, it enhanced the killing of cancer cells more effectively in wild type cell line models than on R521K harboring cells. Although antibody binding assay and EGF receptor phosphorylation was not different among the cell lines used, in vivo xenograft models showed strong antitumor effect of cetuximab in wild type models, and only moderate or no response in EGFR R521K models. Our clinical study, showed significantly lower progression-free survival among patients with R521K tumors. Overall survival of the two genotype groups showed only a trend of similar pattern, without statistically significant difference. Immune cell quantification showed no difference between the NK cell and macrophage infiltration in the two groups. Our data suggests the possible effect of EGFR 521 genotype on cetuximab therapy efficacy, but per se is insufficient to explain the dramatic difference between patient responses. Further data collection and analysis might be needed to reassure if R521K should play role in therapy selection for HNSCC, while clinical samples collected after cetuximab treatment would be exceptionally useful in order to track immune cell changes in patients with wild type and EGFR R521K tumors. This work was funded by the National Research, Development and Innovation Office grant K/116295 (2015). Financial support from the 2019 Thematic Excellence Program (TUDFO/51757/2019-ITM) is greatly acknowledged.
Citation Format: Mihaly T. Cserepes, Zita Hegedus, Ivan Ranđelović, Istvan Kenessey, Mónika Meilinger-Dobra, Kristóf G. Csikó, Andrea Ladanyi, Éva Remenár, Jozsef Tovari. Correlations of genetic variation R521K of EGF receptor and the in vitro, in vivo and clinical phenotypes of head and neck cancers after cetuximab treatment [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1863.
Collapse
Affiliation(s)
| | - Zita Hegedus
- National Institute of Oncology, Budapest, Hungary
| | | | | | | | | | | | - Éva Remenár
- National Institute of Oncology, Budapest, Hungary
| | | |
Collapse
|
7
|
Forster MD, Dillon MT, Kocsis J, Remenár É, Pajkos G, Rolland F, Greenberg J, Harrington KJ. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. Eur J Cancer 2019; 123:36-47. [PMID: 31648099 DOI: 10.1016/j.ejca.2019.08.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 08/13/2019] [Accepted: 08/26/2019] [Indexed: 01/11/2023]
Abstract
BACKGROUND The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) demonstrated tolerability and tumour response of patritumab + cetuximab + platinum. METHODS This was a randomised, double-blind, phase II study of patritumab + cetuximab with platinum-based therapy for first-line treatment of R/M SCCHN (Clinicaltrials.gov identifier: NCT02633800). Patients aged ≥18 years received patritumab or placebo, both combined with cetuximab + cisplatin or carboplatin. Co-primary end-points were progression-free survival (PFS) in the intent-to-treat (ITT) and the high-expression HRG (HRG high) populations. RESULTS Eighty-seven patients (n = 43 in the patritumab group; n = 44 in placebo group) enrolled. A median (range) of 6.5 (1-24) patritumab cycles were completed. Median PFS was similar between the patritumab group and placebo group in the ITT population (5.6 versus 5.5 months; hazard ratio [HR] 0.99 [95% confidence interval [CI], 0.6-1.7]; P = 0.96) and HRG-high subgroup (n = 51; 5.6 versus 5.6 months; HR 0.93 [95% CI, 0.5-1.8]; P = 0.82). Median overall survival in the ITT population was also similar (10.0 versus 12.7 months; HR 1.3 [95% CI, 0.69-2.29]; P = 0.46). All patients experienced ≥1 treatment-emergent adverse event (TEAE). Grade ≥III TEAEs were more frequent in the patritumab than the placebo group (84.1% versus 60.5%). The most common grade ≥III patritumab-related TEAE in the patritumab group (20.5% overall) was rash (6.8%). CONCLUSION Patritumab + cetuximab + platinum was tolerable but not superior to cetuximab + platinum.
Collapse
Affiliation(s)
- Martin D Forster
- Department of Oncology, UCL Cancer Institute/University College London Hospitals, London, UK
| | - Magnus T Dillon
- Head and Neck Unit, Royal Marsden Hospital/Institute of Cancer Research, National Institute of Health Research Biomedical Research Center, London, UK
| | - Judit Kocsis
- Oncology Department, Debrecen University Clinical Center, Debrecen, Hungary; Department of Oncoradiology, Bács-kiskun County Teaching Hospital (BKMK) Centre of Oncoradiology, Kecskemét, Hungary
| | - Éva Remenár
- Hospitalier Order of Saint John of God Hospital Buda, Budapest, Hungary
| | - Gabor Pajkos
- Department of Oncoradiology, Bács-kiskun County Teaching Hospital (BKMK) Centre of Oncoradiology, Kecskemét, Hungary
| | - Frederic Rolland
- Department of Medical Oncology, Institut de Cancerologie de l'Ouest (ICO) - Site René Gauducheau, Saint-Herblain, France
| | | | - Kevin J Harrington
- Head and Neck Unit, Royal Marsden Hospital/Institute of Cancer Research, National Institute of Health Research Biomedical Research Center, London, UK.
| |
Collapse
|
8
|
Ladányi A, Kapuvári B, Papp E, Tóth E, Lövey J, Horváth K, Gődény M, Remenár É. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab. Head Neck 2018; 41:1237-1245. [PMID: 30548478 DOI: 10.1002/hed.25546] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 10/08/2018] [Accepted: 10/17/2018] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND The aim of this study was to determine whether tumor-associated immune cells may predict response to therapy and disease outcome in head and neck squamous cell carcinoma (HNSCC) patients receiving induction chemotherapy and cetuximab. METHODS Paraffin-embedded pretreatment biopsy samples from 45 patients with stage III-IV resectable HNSCC were investigated retrospectively by immunohistochemistry for density of different immune cell types based on expression of CD8, FOXP3, CD134, CD137, PD-1, CD20, NKp46, dendritic cell lysosomal-associated membrane protein (DC-LAMP), CD16, CD68, and myeloperoxidase. Results were analyzed for possible correlations with clinicopathologic parameters, response to therapy, and survival. RESULTS Of the immune cell types studied, we found significant association with response to induction chemotherapy only in the case of DC-LAMP+ mature dendritic cells and PD-1+ lymphocytes; density of DC-LAMP+ cells also correlated with progression-free survival. CONCLUSION DC-LAMP+ mature dendritic cells and PD-1+ cells may be implicated in response to induction chemotherapy and cetuximab in HNSCC patients.
Collapse
Affiliation(s)
- Andrea Ladányi
- Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary
| | - Bence Kapuvári
- Department of Biochemistry, National Institute of Oncology, Budapest, Hungary
| | - Eszter Papp
- Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary
| | - Erika Tóth
- Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary
| | - József Lövey
- Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary
| | - Katalin Horváth
- Department of Diagnostic Radiology, National Institute of Oncology, Budapest, Hungary
| | - Mária Gődény
- Department of Diagnostic Radiology, National Institute of Oncology, Budapest, Hungary
| | - Éva Remenár
- Multidisciplinary Center of Head and Neck Oncology, National Institute of Oncology, Budapest, Hungary
| |
Collapse
|
9
|
Gõdény M, Remenár É, Takácsi-Nagy Z, Petri K, Horváth K, Bõcs K, Manninger S, Andi J, Léránt G, Kásler M. [Role of MRI and CT in the evaluation of postirradiation status and complications in head and neck cancer]. Magy Onkol 2018; 62:159-173. [PMID: 30256882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Accepted: 07/22/2018] [Indexed: 06/08/2023]
Abstract
Most head and neck cancer patients are treated with combined modalities such as surgery, radiotherapy (RT), chemotherapy (ChT). Concurrent chemo-radiation has improved treatment outcomes with increased toxic effects. Reactions after RT are divided into early and late changes. Early reactions are seen during the course of therapy or within 3 months; these are reversible in most cases. Late complications are observed 3 months to years after RT and they are generally irreversible. As typical late reaction radiation induced necrosis may occur in soft tissues, cartilage, bones and brain. Tumor recurrence and post-radiation necrosis typically appear at the same time, within 2-3 years after RT; the differentiation may be difficult. Computed tomography (CT) and magnetic resonance imaging (MRI) have become the gold standards not only for staging and assessing tumor response, but also to evaluate posttreatment status, to distinguish residual or recurrent tumor and RT complications. Using baseline CT or MRI between 2-3 months after treatment and performing standard follow-up imaging with strict clinical follow-up are required to establish early salvage treatment.
Collapse
Affiliation(s)
- Mária Gõdény
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Éva Remenár
- Fej-Nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary
| | | | - Klára Petri
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Katalin Horváth
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Katalin Bõcs
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Sándor Manninger
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Judit Andi
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Gergely Léránt
- Onkológiai Képalkotó és Invazív Diagnosztikai Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Miklós Kásler
- Fej-Nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary
| |
Collapse
|
10
|
Meilinger-Dobra M, Remenár É, Fröhlich G, Sinkovics I, Péter I, Boér A. [Retrospective analysis of papillary thyroid microcarcinoma cases treated between 2001 and 2010 in the Hungarian National Institute of Oncology]. Magy Onkol 2018; 62:153-158. [PMID: 30256881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 08/31/2018] [Indexed: 06/08/2023]
Abstract
The standard treatment of papillary microcarcinomas (mPTC; ≤1 cm) regardless of their size, was similar to the advanced ones till the recent past: immediate surgery ± radioactive iodine (RAI) therapy. However, the American Thyroid Association (ATA) 2015 guidelines accept the active surveillance in selected cases. We performed a retrospective analysis on the clinical data of 103 patients with PTmC in a single (62.1%) or multiple nodes (37.9%), treated with immediate surgery followed in most cases by postoperative RAI between 2001 and 2010. N stage of the neck was pN0 in 81, and pN+ in 22 patients. Survival probability was significantly related to age (p<0.001), TSH level (p=0.0347), N stage (p=0.0402) and need for neck dissection (p=0.0045). Overall survival at 5, 10, and 15 years was 95%, 89%, and 86%, while disease-specific mortality at 5 and 10 years was 3% and 5%, respectively. Our data show that immediate radical surgery with or without postoperative RAI yielded long-term survival similar to those published. Nevertheless, progression affecting mostly older men was not prevented by immediate surgery. Our findings do not contradict the acceptability of active surveillance recommended by the 2015 ATA Guidelines.
Collapse
Affiliation(s)
- Mónika Meilinger-Dobra
- Fej-Nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Éva Remenár
- Fej-Nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| | - Georgina Fröhlich
- Sugárterápiás Központ, Országos Onkológiai Intézet, Budapest, Hungary
| | - István Sinkovics
- Nukleáris Medicina Osztály, Országos Onkológiai Intézet, Budapest, Hungary
| | - Ilona Péter
- Daganatpatológiai Központ, Országos Onkológiai Intézet, Budapest, Hungary
| | - András Boér
- Fej-Nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary.
| |
Collapse
|
11
|
Bellyei S, Bakó P, Orosz É, Molnár K, Remenár É, Mangel L. [First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma]. Magy Onkol 2018; 62:175-178. [PMID: 30256884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2018] [Accepted: 07/11/2018] [Indexed: 06/08/2023]
Abstract
The prognosis for recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) remains dismal and its treatment poses a challenge for oncologists. Nivolumab belongs to the class of immune checkpoint inhibitors (ICI) and is an antibody developed to target the programmed cell death protein 1 (PD-1) receptor. The CheckMate 141 randomized phase 3 trial proved the efficacy of nivolumab in the treatment of R/M HNSCC as it was shown to significantly increase overall survival and quality of life. We present the case of a 53-year-old woman with R/M HNSCC who was given nivolumab monotherapy, as third-line treatment due the progression of her tumor. After treatment with nivolumab, the size of her tumor decreased, then was stable, while she did not experience any adverse events or notable side effects. Our case report is the first to demonstrate the application of nivolumab in R/M HNSCC in Hungary.
Collapse
Affiliation(s)
| | - Péter Bakó
- Fül-Orr-Gégészeti és Fej-Nyaksebészeti Klinika, PTE KK, Pécs, Hungary
| | - Éva Orosz
- Fül-Orr-Gégészeti és Fej-Nyaksebészeti Klinika, PTE KK, Pécs, Hungary
| | | | - Éva Remenár
- Fej-Nyaki Daganatok Multidiszciplináris Központ, Országos Onkológiai Intézet, Budapest, Hungary
| | | |
Collapse
|
12
|
Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenár É, Degardin M, Pateras IS, Langendijk JA, van Herpen CML, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. Ann Oncol 2018. [PMID: 28651338 DOI: 10.1093/annonc/mdx320] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Background EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil), in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable head and neck squamous cell carcinomas. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(-) patients (pts) benefit from adding docetaxel to PF, in which case deintensifying induction treatment in HPV(+) pts could be considered. Patients and methods Pretherapy tumor biopsies (blocks or slides) were assessed for high-risk HPV by p16 immunohistochemistry, PCR and quantitative PCR. HPV-DNA+ and/or p16+ tumors were subjected to in situ hybridization (ISH) and HPV E6 oncogene expression qRT-PCR analysis. Primary and secondary objectives were to evaluate the value of HPV/p16 status as predictive factor of treatment benefit in terms of PFS and OS. The predictive effect was analyzed based on the model used in the primary analysis of the study with the addition of a treatment by marker interaction term and tested at two-sided 5% significance level. Results Of 358, 119 pts had available tumor samples and 58 of them had oropharyngeal cancer. Median follow-up was 8.7 years. Sixteen of 119 (14%) evaluable samples were p16+ and 20 of 79 (25%) evaluable tumors were HPV-DNA+. 13 of 40 pts (33%) assessed with HPV-DNA ISH and 12 of 28 pts (43%) assessed for HPV E6 mRNA were positive. The preplanned analysis showed no statistical evidence of predictive value of HPV/p16 status for PFS (P = 0.287) or OS (P = 0.118). Conclusions The incidence of HPV positivity was low in the subset of EORTC 24971 pts analyzed. In this analysis only powered to detect a large treatment by marker interaction, there was no statistical evidence that treatment effect found overall was different in magnitude in HPV(+) or HPV(-) pts. These results do not justify selection of TPF versus PF according to HPV status.
Collapse
Affiliation(s)
- A Psyrri
- Section of Medical Oncology, Second Department of Internal Medicine, School of Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | | | - G Koutsodontis
- Section of Medical Oncology, Second Department of Internal Medicine, School of Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - M Avgeris
- Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece
| | - C Kroupis
- Department of Clinical Biochemistry, School of Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - N Goutas
- Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - J Menis
- EORTC Headquarters, Brussels, Belgium
| | - L Herman
- EORTC Headquarters, Brussels, Belgium
| | - L Giurgea
- EORTC Headquarters, Brussels, Belgium
| | - É Remenár
- Department of Head and Neck Surgery, National Institute of Oncology, Budapest, Hungary
| | - M Degardin
- Department of Oncology, Centre Oscar Lambret, Lille, France
| | - I S Pateras
- Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - J A Langendijk
- Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - C M L van Herpen
- Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - A Awada
- Medical Oncology Clinic, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
| | - J R Germà-Lluch
- Institut Català d'Oncologia, ICO L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - H R Kienzer
- 3rd Medical Department, Oncology and Hematology Center, Kaiser Franz Josef Spital/SMZ Sud, Vienna, Austria
| | - L Licitra
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, and University of Milan, Milan, Italy
| | - J B Vermorken
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
| |
Collapse
|
13
|
Soulières D, Licitra L, Mesía R, Remenár É, Li SH, Karpenko A, Chol M, Wang YA, Solovieff N, Bourdeau L, Sellami D, Faivre S. Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. Clin Cancer Res 2018; 24:2505-2516. [PMID: 29490986 DOI: 10.1158/1078-0432.ccr-17-2644] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 01/17/2018] [Accepted: 02/22/2018] [Indexed: 12/24/2022]
Abstract
Purpose: The preplanned exploratory analysis of the BERIL-1 trial presented here aimed to identify biomarkers of response to the combination of buparlisib and paclitaxel.Patients and Methods: BERIL-1 was a multicenter, randomized, double-blind, placebo-controlled phase II study. Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on/after one previous platinum-based chemotherapy regimen in the recurrent or metastatic setting were treated with either buparlisib plus paclitaxel or placebo plus paclitaxel. Archival tumor tissue and ctDNA samples were analyzed for molecular alterations and immune infiltration using next-generation sequencing or immunohistochemistry.Results: Biomarker analyses were performed in randomized patients (n = 158) with available biomarker data. The most frequently (>5%) mutated genes were TP53, FAT1, TET2, KMT2D, PIK3CA, NOTCH1, NFE2L2, NOTCH2, CCND1, and CDKN2A Patients with SCCHN tumors (from various primary sites) having HPV-negative status (HR = 0.51), TP53 alterations (HR = 0.55) or low mutational load (HR = 0.57) derived overall survival (OS) benefit with the combination of buparlisib and paclitaxel. OS benefit with this combination was also increased in patients with presence of intratumoral TILs ≥10% (HR = 0.51), stromal TILs ≥15% (HR = 0.53), intratumoral CD8-positive cells ≥5% (HR = 0.45), stromal CD8-positive cells ≥10% (HR = 0.47), or CD8-positive cells in invasive margins >25% (HR = 0.37). A trend for improved progression-free survival with the combination of buparlisib and paclitaxel was also observed in these patients.Conclusions: The BERIL-1 biomarker analyses showed that patients with TP53 alterations, HPV-negative status, low mutational load, or high infiltration of TILs or CD8-positive cells derived survival benefit with the combination of buparlisib and paclitaxel. Clin Cancer Res; 24(11); 2505-16. ©2018 AACR.
Collapse
Affiliation(s)
- Denis Soulières
- Centre Hospitalier de l'Université de Montréal, Montréal, Canada
| | - Lisa Licitra
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and University of Milan, Milan, Italy
| | - Ricard Mesía
- Institut Català d'Oncologia-L'Hospitalet, Universitat de Barcelona, IDIBELL, Barcelona, Spain
| | - Éva Remenár
- Országos Onkológiai Intézet, Budapest, Hungary
| | - Shau-Hsuan Li
- Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
| | - Andrey Karpenko
- Leningrad Regional Oncology Dispensary, Saint Petersburg, Russian Federation
| | | | - Ying A Wang
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | - Nadia Solovieff
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
| | | | - Dalila Sellami
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
| | - Sandrine Faivre
- Hôpitaux Universitaires Paris Nord Val de Seine, Paris, France.
| |
Collapse
|
14
|
Gődény M, Lengyel Z, Polony G, Nagy ZT, Léránt G, Zámbó O, Remenár É, Tamás L, Kásler M. Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis. Cancer Imaging 2016; 16:38. [PMID: 27814768 PMCID: PMC5096285 DOI: 10.1186/s40644-016-0097-x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 10/26/2016] [Indexed: 02/06/2023] Open
Abstract
Background This study aimed to determine the ability of multimodal evaluation with multiparametric 3T-MRI (MPMRI) and positron emission tomography - computed tomography (PET/CT) to detect cancer of unknown primary origin (CUP) with neck lymph node (LN) metastasis. Methods The study group comprised 38 retrospectively analysed consecutive patients with LN metastasis in the head and neck (HN) region without known primary tumours (PTs). Statistical values of 3T-MRI and of FDG-PET/CT scans were evaluated. Results Of the 38 CUPs, conventional native T1-, T2-weighted and STIR sequences detected 6 PTs. Native sequences plus diffusion-weighted imaging (DWI) found 14-, and with fat suppression contrast-enhanced T1-weighted measurement as well as with the complex MPMRI found 15 primaries and with PET/CT 17 CUPs could be evaluated, respectively. The detection rates were 15.8, 36.8, 39.5, 39.5 and 44.7 % for conventional native MRI, native plus DWI, native with contrast-enhanced MRI (CE-MRI), for MPMRI, and for PET/CT, respectively. The overall detection rate proved by histology was 47.4 %. PET/CT provided the highest sensitivity (Sv: 94.4 %) but a lower specificity (Sp: 65.0 %), using MPMRI (Sv: 88.2 %) the specificity increased to 71.4 %. DWIincreased specificity of the native sequences (Sp: 76.2 %). Conventional native sequences plus DWI as well as 3T-MPMRI and PET/CT were same accurate (Acc: 79.0 %) and had similar likelihood ratio (LR: 3.42, 3.03 and 2.62) in detecting unknown PT sites. Conclusions The accuracy of FDG-PET/CT and MPMRI in case of CUP in finding the primary cancer in the neck regions is identical. While using PET/CT whole body information can be obtained in one examination. MPMRI shows the local soft tissue status more accurately. In cases of CUP PET/CT should be the first method of choice if it is available. MPMRI can clarify the exact primary tumor stage, and it can be advantageous in clarifying the prognostic factors, which is necessary in case of advanced tumor stage and when surgery is under consideration. In case low N stage is likely after the clinical examination and wait and see policy can be considered, MPMRI is recommended, and in this case the significance the of radiation free MPMRI is increasing. Electronic supplementary material The online version of this article (doi:10.1186/s40644-016-0097-x) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Mária Gődény
- Department of Diagnostic Radiology, National Institute of Oncology, Ráth György street 7-9, Budapest, 1122, Hungary. .,Department of Postgraduate Education and Scientific Research, University of Medicine and Pharmacy, Tirgu Mures, Romania.
| | - Zsolt Lengyel
- Pozitron Diagnostics LTD, Hunyadi János street 9, Budapest, 1117, Hungary
| | - Gábor Polony
- Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Szigony u.36, Budapest, 1083, Hungary
| | - Zoltán Takácsi Nagy
- Department of Radiotherapy, National Institute of Oncology, Ráth György street 7-9, Budapest, 1122, Hungary
| | - Gergely Léránt
- Department of Diagnostic Radiology, National Institute of Oncology, Ráth György street 7-9, Budapest, 1122, Hungary
| | - Orsolya Zámbó
- Head and Neck Surgery Department, National Institute of Oncology, Ráth György street 7-9, Budapest, 1122, Hungary
| | - Éva Remenár
- Head and Neck Surgery Department, National Institute of Oncology, Ráth György street 7-9, Budapest, 1122, Hungary
| | - László Tamás
- Department of Otorhinolaryngology, Head and Neck Surgery, Semmelweis University, Szigony u.36, Budapest, 1083, Hungary
| | - Miklós Kásler
- Head and Neck Surgery Department, National Institute of Oncology, Ráth György street 7-9, Budapest, 1122, Hungary.,Department of Postgraduate Education and Scientific Research, University of Medicine and Pharmacy, Tirgu Mures, Romania
| |
Collapse
|
15
|
Hitre E, Budai B, Takácsi-Nagy Z, Rubovszky G, Tóth E, Remenár É, Polgár C, Láng I. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 2013; 109:1117-22. [PMID: 23942070 PMCID: PMC3778310 DOI: 10.1038/bjc.2013.468] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2013] [Revised: 07/12/2013] [Accepted: 07/21/2013] [Indexed: 12/13/2022] Open
Abstract
Background: Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with concomitant platinum-based chemoradio- or chemotherapy in patients with locally advanced or metastatic ACC, respectively, was evaluated. Methods: Eligible patients (9 with locally advanced tumour and 12 with metastases) had positive tumour EGFR expression. The cetuximab loading dose (400 mg m−2) was followed by 250 mg m−2 per week. Locally advanced tumours were irradiated (mean dose 65 Gy) and treated with concomitant cisplatin (75 mg m−2, intravenously). Patients with metastases received concomitant cisplatin and 5-fluorouracil (4 × 1000 mg m−2). Results: For patients with locally advanced disease (median follow-up: 52 months), the median progression-free survival (PFS) was 64 months and the 2-year overall survival (OS) rate was 100%. For patients with metastases (median follow-up: 72 months), the median PFS and OS were 13 and 24 months, respectively. In both groups the objective response rate was >40%. Skin rash, in-field dermatitis, mucositis and vomiting were the most frequent grade 3/4 adverse events. Conclusion: In this single-arm study, the efficacy of cetuximab plus chemoradio- or chemotherapy appeared favourable as compared with historical controls. All side effects were manageable and did not hamper the treatment.
Collapse
Affiliation(s)
- E Hitre
- National Institute of Oncology, Ráth Gy. u. 7-9, 1122 Budapest, Hungary
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Licitra L, Mesia R, Rivera F, Remenár É, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2010; 22:1078-1087. [PMID: 21048039 PMCID: PMC3082162 DOI: 10.1093/annonc/mdq588] [Citation(s) in RCA: 175] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Background: The phase III EXTREME study demonstrated that combining cetuximab with platinum/5-fluorouracil (5-FU) significantly improved overall survival in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) compared with platinum/5-FU alone. The aim of this investigation was to evaluate elevated tumor EGFR gene copy number as a predictive biomarker in EXTREME study patients. Patients and methods: Dual-color FISH was used to determine absolute and relative EGFR copy number. Models of differing stringencies were used to score and investigate whether increased copy number was predictive for the activity of cetuximab plus platinum/5-FU. Results: Tumors from 312 of 442 patients (71%) were evaluable by FISH and met the criteria for statistical analysis. A moderate increase in EGFR copy number was common, with high-level amplification of the gene occurring in a small fraction of tumors (∼11%). Considering each of the models tested, no association of EGFR copy number with overall survival, progression-free survival or best overall response was found for patients treated with cetuximab plus platinum/5-FU. Conclusion: Tumor EGFR copy number is not a predictive biomarker for the efficacy of cetuximab plus platinum/5-FU as first-line therapy for patients with R/M SCCHN.
Collapse
Affiliation(s)
- L Licitra
- Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy
| | - R Mesia
- Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain
| | - F Rivera
- Medical Oncology Department, Marqués de Valdecilla University Hospital, Santander, Spain
| | - É Remenár
- Head and Neck Department, National Institute of Oncology, Budapest, Hungary
| | - R Hitt
- Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
| | - J Erfán
- Department of Oncoradiology, Jósa András County Hospital, Nyíregyháza, Hungary
| | - S Rottey
- Medical Oncology, Ghent University Hospital, Gent, Belgium
| | - A Kawecki
- Head and Neck Cancer Department, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
| | - D Zabolotnyy
- Institute of Otolaryngology, Academy of Medical Sciences of Ukraine, Kiev, Ukraine
| | - M Benasso
- Oncology Department, San Paolo Hospital, Savona, Italy
| | - S Störkel
- Institute of Pathology, HELIOS Hospital Wuppertal, Wuppertal, Germany
| | | | - C Stroh
- Oncology Research, Merck KGaA, Darmstadt, Germany
| | - J B Vermorken
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
| |
Collapse
|
17
|
Olasz J, Juhász A, Remenár É, Engi H, Bak M, Csuka O, Kásler M. RARβ2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age. Oncol Rep 2007. [DOI: 10.3892/or.18.1.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
18
|
Timar professor J, Lukits J, Rásó E, Kásler M, Remenár É. Molecular identification, expression and prognostic role of estrogen alpha, beta and progesteron receptors in head and neck cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20056 Background: Previous data suggested hormone receptor protein expressions in head and neck cancer (HNC), but the molecular identification of the receptors was lacking and the prognostic significance was unclear. Methods: Sixty seven freshly frozen surgical samples of HNC patients were used throughout the study. Sex hormone receptor protein expression (ERa, Erb and PgR) of tumor cells was determined by immunocytochemistry. In case of positive reaction, data have been confirmed at mRNA level by nested-PCR and sequencing. Prognostic significance of the hormone receptor expression was determined by statistical analysis of the 4 year survival of the patients. Results: ER and PgR expressions confirmed by PCR analysis were frequent in HNC: 50.7 and 49.3%, respectively. Concerning the ER isoforms, ERa was predominant (41.8%) over ERb (28.4%) in both of oral as well as glottic cancers. The incidence of functional receptor expression (coexpression of ER and PgR) was relatively frequent in HNC: 41.8% which was independent of the anatomical location of the tumor. A minimum of 3 year follow up data were available for 51 HNC patients. Sex hormone receptor expressions did not affect survival, however, in the glottic cancer subgroup (n = 36) the ER expression was associated with a shortened 4 survival (23.1 versus 65.0%, respectively). Conclusions: ERa,b and PgR expression is frequent in HNC and may affect the prognosis of the disease at least in case of glottic cancer. On the other hand, the frequent coexpression of ER isoforms with PgR in HNC raises the possibility of clinical application of selective estrogen receptor modulators in this cancer type.This work is supported by the grant NKFP1a-0024–05. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - J. Lukits
- National Institute of Oncology, Budapest, Hungary
| | - E. Rásó
- National Institute of Oncology, Budapest, Hungary
| | - M. Kásler
- National Institute of Oncology, Budapest, Hungary
| | - É. Remenár
- National Institute of Oncology, Budapest, Hungary
| |
Collapse
|
19
|
Lövey J, Koronczay K, Remenár É, Csuka O, Németh G. Low-dose paclitaxel radiosensitization in locally advanced head and neck cancers. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80878-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Csuka O, Németh G, Koronczay K, Doleschall Z, Remenár É. 819 Significance of p53 and bcl2 levels in the radio-sensitivity of head and neck cancer. Eur J Cancer 1995. [DOI: 10.1016/0959-8049(95)96068-o] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|